Exero Medical
Exero’s Pivotal Clinical Study Approved by WCG
Exero’s multi-center study expected to commence during Q1 2024.
Can-Fite
CAN-FITE expands license deal with Ewopharma
Exclusive distribution agreement for psoriasis and hepatocellular carcinoma (HCC) and nonalcoholic steatohepatitis (NASH).
Mediwound
Mediwound announces positive data from clinical study
Phase I/II study evaluated safety and efficacy of MW005 for low-risk Basal Cell Carcinoma (BCC).
Cathworks
Cathworks announces first patient in clinical trial
Evaluates the clinical benefits of FFRangio® System in coronary artery disease (CAD)
Nanox
Nanox.AI New Global Partnership with Ferrum Health
Partnership on AI platform – Bone solution (HealthOST) and cardiac solution (HealthCCSng)
Exero
Unorthodox Ventures Invests in Exero Medical
Unorthodox and Founder Carey Smith provide bridge financing toward a series A round
DiA
DiA Secures FDA Clearance for its New AI Software
LVivo IQS for cardiac ultrasound users with real-time image quality feedback while scanning
Mor Research Applications
Purple Biotech Inks Deal With Mor
The agreement provides Purple first access to early-stage oncology product candidates owned by Mor
